HIV vaccine - PX Therapeutics

Drug Profile

HIV vaccine - PX Therapeutics

Alternative Names: EN41-FPA2 HIV; EN41-FPA2 HIV vaccine candidate - PX Therapeutics; EN41-UGR7C; EN41-UGR7C HIV vaccine candidate - PX Therapeutics; EuroNeut41 prophylactic HIV vaccine - PX Therapeutics; HIV vaccine - PX'Therapeutics

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator PX Therapeutics
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-infections(Prevention, In volunteers) in United Kingdom (IM, Injection)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-infections(Prevention, In volunteers) in United Kingdom (Intranasal)
  • 01 Feb 2014 PX Therapeutics completes a phase I trial of EN41-UGR7C for HIV infections (prevention; in volunteers) in United Kingdom (NCT01827397)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top